drugset

drugset / Trial / NCT03725865

A Clinical Study of iNSC Intervent Cerebral Hemorrhagic Stroke

NCT03725865 ↗

Phase 0 Unknown 12 enrolled Allife Medical Science and Technology Co., Ltd.

SequentialOpen-labelTreatment

Summary

This is a single centre、single arm、open-label，to investigate the safety and efficacy of induction of neural stem cells transplantation in the brain

Timeline

Start: 2019-03
Primary completion: 2019-03
Completion: 2019-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	iNSC	Cell therapy	—	Other

Indications